Heartseed Narrows Quarterly Loss but Projects Deeper Full-Year Deficit

Heartseed, Inc. ( (JP:219A) ) has provided an announcement.

Heartseed Inc. reported non-consolidated net sales of ¥465 million for the three months ended March 31, 2026, with an operating loss of ¥75 million and a net loss of ¥58 million, narrowing per-share losses to ¥2.54. The company’s financial position remains solid with total assets of ¥7.6 billion and an equity ratio of 93.8%, and it continues to refrain from dividend payments as it prioritizes investment in its business.

For the full year ending December 31, 2026, Heartseed forecasts modest net sales of ¥467 million alongside a significantly larger operating loss of ¥2.2 billion and a projected net loss of ¥2.2 billion, or ¥94.44 per share. The forecast, which has been revised from prior guidance, underscores the company’s expectation of substantial costs ahead and signals ongoing earnings pressure for shareholders despite a strong capital base.

More about Heartseed, Inc.

Heartseed Inc. is a Tokyo Stock Exchange-listed biotechnology company focused on developing regenerative medicine therapies. The company operates under Japanese GAAP and remains in an early commercial phase, with limited net sales and a continued emphasis on research and development, reflected in ongoing operating losses and a high equity-to-asset ratio.

Average Trading Volume: 296,977

Technical Sentiment Signal: Sell

Current Market Cap: Yen40.26B

See more insights into 219A stock on TipRanks’ Stock Analysis page.